These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36952005)

  • 1. Comparison of stereotactic body radiotherapy with and without lenvatinib for advanced hepatocellular carcinoma: a propensity score analysis.
    Wang Q; Ji X; Sun J; Li W; Duan X; Zhang A
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7441-7452. PubMed ID: 36952005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study.
    Ji X; Xu Z; Sun J; Li W; Duan X; Wang Q
    Radiat Oncol; 2023 Jun; 18(1):101. PubMed ID: 37308914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic body radiotherapy versus lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity matching score analysis.
    Ji X; Zhang A; Duan X; Wang Q
    Radiat Oncol; 2024 Oct; 19(1):143. PubMed ID: 39394613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study.
    Xia D; Bai W; Wang E; Li J; Chen X; Wang Z; Huang M; Huang M; Sun J; Yang W; Lin Z; Wu J; Li Z; Yang S; Zhu X; Chen Z; Zhang Y; Fan W; Mai Q; Ding R; Nie C; Feng L; Li X; Huang W; Sun J; Wang Q; Lv Y; Li X; Luo B; Wang Z; Yuan J; Guo W; Li K; Li B; Li R; Yin Z; Xia J; Han G
    Liver Cancer; 2022 Jul; 11(4):368-382. PubMed ID: 35978600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic Body Radiotherapy Combined With Lenvatinib With or Without PD-1 Inhibitors as Initial Treatment for Unresectable Hepatocellular Carcinoma.
    Wang Q; Ji X; Sun J; Zhang A; Jia J; Zhang T; Li W; Duan X
    Int J Radiat Oncol Biol Phys; 2024 Dec; 120(5):1363-1376. PubMed ID: 38583495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idarubicin-Loaded DEB-TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score-matching analysis.
    Fan W; Zhu B; Yue S; Zheng X; Zou X; Li F; Qiao L; Wu Y; Xue M; Wang H; Tang Y; Li J
    Cancer Med; 2023 Jan; 12(1):61-72. PubMed ID: 35698292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of anti-PD-1 monotherapy
    Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
    Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study.
    Jin ZC; Zhong BY; Chen JJ; Zhu HD; Sun JH; Yin GW; Ge NJ; Luo B; Ding WB; Li WH; Chen L; Wang YQ; Zhu XL; Yang WZ; Li HL; Teng GJ;
    Eur Radiol; 2023 Dec; 33(12):8669-8681. PubMed ID: 37368105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thermal Ablation Versus Stereotactic Body Radiotherapy After Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis.
    Nabavizadeh N; Jahangiri Y; Rahmani R; Tomozawa Y; Geeratikun Y; Chen Y; Hung A; Degnin C; Farsad K
    AJR Am J Roentgenol; 2021 Sep; 217(3):691-698. PubMed ID: 32997517
    [No Abstract]   [Full Text] [Related]  

  • 10. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
    Xu YJ; Lai ZC; He MK; Bu XY; Chen HW; Zhou YM; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M; Li QJ
    Technol Cancer Res Treat; 2021; 20():15330338211063848. PubMed ID: 34898313
    [No Abstract]   [Full Text] [Related]  

  • 11. The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study.
    Chen J; Xiong P; Nie M; Pan Y; Wang J; Hu D; Zhou Z; Zhang Y; Chen M; Xu L
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2491-2500. PubMed ID: 35752744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.
    Rimini M; Rimassa L; Ueshima K; Burgio V; Shigeo S; Tada T; Suda G; Yoo C; Cheon J; Pinato DJ; Lonardi S; Scartozzi M; Iavarone M; Di Costanzo GG; Marra F; Soldà C; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Pressiani T; Nishida N; Iwamoto H; Sakamoto N; Ryoo BY; Chon HJ; Claudia F; Niizeki T; Sho T; Kang B; D'Alessio A; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimur T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Pedica F; De Cobelli F; Ratti F; Aldrighetti L; Kudo M; Cascinu S; Casadei-Gardini A
    ESMO Open; 2022 Dec; 7(6):100591. PubMed ID: 36208496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic Arterial Infusion Chemotherapy Combined Lenvatinib and PD-1 Inhibitor Showed Improved Survival for Infiltrative Hepatocellular Carcinoma: A Multicenter Cohort Study.
    Li R; Wang X; Li H; Wang M; Wang J; Wang W; Zhou Q
    J Hepatocell Carcinoma; 2024; 11():1727-1740. PubMed ID: 39281003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
    Li LQ; Zhou Y; Huang Y; Liang P; Liang SX; Su TS
    Hepatol Int; 2021 Jun; 15(3):630-641. PubMed ID: 33818714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma.
    Su CW; Teng W; Lin PT; Jeng WJ; Chen KA; Hsieh YC; Chen WT; Ho MM; Hsieh CH; Wang CT; Chai PM; Lin CC; Lin CY; Lin SM
    Cancer Med; 2023 Mar; 12(6):7077-7089. PubMed ID: 36468578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
    Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
    Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications.
    Sun X; Zhang Q; Mei J; Yang Z; Chen M; Liang T
    BMC Cancer; 2022 Mar; 22(1):293. PubMed ID: 35305593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies.
    Long Y; Liang Y; Li S; Guo J; Wang Y; Luo Y; Wu Y
    Radiat Oncol; 2021 Apr; 16(1):68. PubMed ID: 33832536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiotherapy versus hepatic resection for hepatocellular carcinoma (≤ 5 cm): a propensity score analysis.
    Sun J; Wang Q; Hong ZX; Li WG; He WP; Zhang T; Zhang AM; Fan YZ; Sun YZ; Zheng L; Duan XZ
    Hepatol Int; 2020 Sep; 14(5):788-797. PubMed ID: 32886334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiotherapy plus transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma patients with portal vein tumour thrombus: A meta-analysis.
    Zhang XF; Lai L; Zhou H; Mo YJ; Lu XQ; Liu M; Lu YX; Hou EC
    PLoS One; 2022; 17(5):e0268779. PubMed ID: 35594278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.